Trials / Completed
CompletedNCT01303978
Phase II Proof-of-concept Study of APD421
Open-label, Ascending-dose, Phase II Study to Determine the Minimum Effective Dose of APD421 in the Prevention of Cisplatin-induced Nausea and Vomiting
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Acacia Pharma Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of efficacy of APD421 in preventing nausea and vomiting caused by cisplatin
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APD421 | Single dose |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2012-07-01
- Completion
- 2012-07-01
- First posted
- 2011-02-25
- Last updated
- 2012-09-25
Locations
4 sites across 2 countries: Denmark, United Kingdom
Source: ClinicalTrials.gov record NCT01303978. Inclusion in this directory is not an endorsement.